Sermorelin Reference Guide

Compound Reference Overview

Field Value
Name Sermorelin
Reference Code SERM
Category Growth Hormone-Releasing Hormone (GHRH) Analog
Example Strengths 5 mg, 10 mg (varies by formulation)
Reference Range 200–500 mcg once daily (literature-based clinical use)
Frequency Once daily (typically bedtime administration)
Key Safety Warning Not FDA-approved for anti-aging use. Contraindicated in active malignancy and pituitary tumors. Antibody formation has been reported with prolonged use, which may reduce therapeutic effectiveness.

Mechanism of Action (Educational)

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1–29), the endogenous hypothalamic peptide responsible for stimulating growth hormone (GH) secretion.

It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating pulsatile release of growth hormone in a physiologic pattern.

Downstream effects include increased hepatic production of insulin-like growth factor-1 (IGF-1), which mediates many of the anabolic and metabolic actions associated with GH.

Indications (Literature / Clinical Context)

  • Diagnosed growth hormone deficiency
  • IGF-1 modulation research
  • Body composition investigations
  • Sleep quality and recovery studies

Administration (Literature)

Parameter Details
Route Subcutaneous
Frequency Once daily
Injection Sites Abdomen, thigh (rotate sites)
Timing Bedtime preferred; typically administered on an empty stomach

Pharmacokinetics (Literature)

Sermorelin has a short plasma half-life of approximately 10–20 minutes.

Growth hormone release is typically observed within minutes following administration, with downstream IGF-1 increases occurring over days to weeks.

Glucocorticoids may blunt the GH response to GHRH analogs.

Titration Schedule (Literature-Based Example)

  • Weeks 1–2: 200 mcg at bedtime
  • Weeks 3–4: 300 mcg at bedtime
  • Week 5+: 300–500 mcg at bedtime

Dose adjustments are typically guided by IGF-1 levels and tolerability.

Reconstitution & Concentration (Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 100 mcg. This supports clean unit-to-microgram conversion across escalation stages.

Parameter Value
Target Concentration 1 mg/mL (1000 mcg/mL)
Unit Conversion 0.10 mL (10 units) = 100 mcg
Example (5 mg vial) Reconstitute with 5.0 mL bacteriostatic water → 1 mg/mL
Stability Up to 28 days refrigerated (2–8°C; varies by formulation)

Conversion Reference

  • 10 units = 100 mcg
  • 20 units = 200 mcg
  • 30 units = 300 mcg
  • 50 units = 500 mcg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance.

Safety & Contraindications (Summary)

Contraindications

  • Active malignancy
  • Pituitary tumors
  • Pregnancy or breastfeeding

Drug Interactions

  • Glucocorticoids may inhibit GH response

Adverse Events

  • Injection site reactions
  • Facial flushing
  • Headache
  • Dizziness

Rare Events

  • Allergic reactions
  • Antibody formation with prolonged use

Monitoring (Literature)

  • IGF-1 levels
  • Fasting glucose
  • Clinical response and tolerability

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

Sermorelin is not FDA-approved for anti-aging or body composition purposes. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources